IDH1 and central nervous system cancer: Among glioma subtypes, IDH1/2 mutant glioma has undergone one of the most significant reclassifications in the shift from histopathologic to molecular criteria, with nearly half of these tumors formerly diagnosed as glioblastoma or other non-astrocytic gliomas (Brat et al., 2020).